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Abstract
Background: Transcription factor 7-like 2 gene (TCF7L2), fat mass and obesity-associated gene (FTO), and ectonucleotide 
pyrophosphatase/phosphodiesterase gene (ENPP1) are known risk loci for type 2 diabetes (T2DM) mostly in European 
populations. 
Objectives: To assess the association of  these genes with T2DM risk in a South African mixed-ancestry population.
Methods: Five hundred and sixty six participants were genotyped for ENPP1-rs997509 and -rs1044498, FTO-9941349 and 
-rs3751812, TCF7L2-rs12255372 and -rs7903146 polymorphisms using Taqman genotyping assays and validated by auto-
mated sequencing to assess the association of  the polymorphisms with cardiometabolic traits. 
Results: In logistic regression models adjusted for age, sex, body mass index (BMI) and insulin resistance, minor allele of  
rs997509 was associated with a higher risk of  prevalent T2DM under a recessive model [odd ratio 4.60 (95% confidence 
interval: 1.07 to 19.86); p = 0.040].Under additive model, the rs7903146 [1.43 (1.00 to 2.04); p= 0.053] and rs9941349 [1.43 
(1.00 to 2.04); p = 0.052] minor alleles showed marginally significant associations with a high risk of  T2DM. However, only 
the rs7903146 alleles (p=0.011) and genotypes (p=0.025) distributions were statistically significantly different between dia-
betic and non-diabetic individuals.  
Conclusion: Our findings demonstrate that ENPP1, TCF7L2, and FTO may predispose to T2DM in the mixed-ancestry 
population. 
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Introduction
The completion of  the human genome a decade ago 
has paved a way for a better understanding of  the ge-
netic basis of  common and complex diseases. Through 
candidate gene and linkage analyses, and recently ge-
nome wide association studies (GWAS), several single 
nucleotide polymorphisms (SNPs) have been reported 
as risk loci for type 2 diabetes in European (39 loci) 
and Asian (19 loci) population groups1,2. The majority 
of  these loci seem to influence beta-cell function and 
insulin sensitivity, although the mechanisms by which 
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they impair such functions are yet to be determined. 
Among these loci are transcription factor 7-like 2 gene 
(TCF7L2), fat mass and obesity-associated gene (FTO), 
and ectonucleotide pyrophosphatase/phosphodiester-
ase gene (ENPP1). 
Transcription factor 7-like 2 gene is the first T2DM risk 
locus to be identified through large-scale association 
analyses in European populations3.  The protein encod-
ed by the TCF7L2 is a transcription factor of  the Wnt 
signalling pathway, which plays a crucial role in beta-cell 
function, insulin secretion, and proglucagon gene ex-
pression4, 5. The first surge of  T2DM GWA identified 
among others the fat mass and obesity-associated gene 
(FTO), which is the strongest obesity genetic risk factor 
reported so far6,7. It has been shown to confer suscep-
tibility to T2DM in the presence8,9 and absence of  obe-
sity10,11. The most widely studied SNP of  the ENPP1, 
K121Q (rs1044498), has produced conflicting results 
in relation to T2DM susceptibility12-14. The ENPP1-en-
coded protein (also known as plasma cell-1, PC-1) is a 
class II transmembrane glycoprotein that interacts with 
insulin receptor and inhibits subsequent insulin-signal-
ling through its impaired beta-subunit autophosphoryl-
ation, thus causing insulin resistance15.
 
Although few number of  T2DM susceptibility genes 
discovered through candidate gene, linkage analyses, 
and GWA studies elsewhere have been replicated in Af-
rican studies16-21, it must also be emphasized that many 
other association studies failed to show significant and 
replicable findings22-24. Therefore in this study we inves-
tigated three genes, namely, TCF7L2, FTO, and ENPP1 
as risk factors for T2DM in a South African ethnic pop-
ulation group of  Mixed-ancestry (Coloureds) with a 
unique genetic architecture. Structure analysis conduct-
ed in this population revealed that its origin is predom-
inantly Khoesan (32-43%), Bantu-speaking African 




Ethical approval of  the study
The study was approved by the Faculty of  Health and 
Wellness Sciences Ethics Committee of  the Cape Pen-
insula University of  Technology (CPUT) NHREC: 
REC-230408-014, and was conducted according to the 
code of  ethics of  the World Medical Association (Dec-
laration of  Helsinki). All participants who were recruit-
ed for the study voluntarily signed written consent after 
the procedures had been fully explained in the language 
of  their choice.  Permission to conduct the study was 
granted by relevant authorities such as city and commu-
nity authorities.  
Study design and population
The present study was cross-sectional by design, involv-
ing participants from a mixed-ancestry ethnic popula-
tion group residing in Bellville South township in Cape 
Town, South Africa. The population group has lived in 
Bellville South since late 1950s. A detailed description 
of  the survey and procedures conducted in the study 
are available elsewhere26,27. 
Clinical data
Clinical data was collected in the form of  a standard-
ized questionnaire. During this time, physical examina-
tion was conducted with data collection on blood pres-
sure according to World Health Organisation (WHO) 
guidelines28 using a semi-automatic digital blood pres-
sure monitor (Rossmax PA, USA) on the right arm in 
sitting position, and anthropometric measurements; 
body weight was measured to the nearest 0.1 kg with 
a Sunbeam EB710 digital bathroom scale, which was 
calibrated and standardized using a weight of  known 
mass. Measurements were recorded with each subject 
wearing light clothing, without shoes and socks. Waist 
circumference was determined using a non-elastic tape 
at the level of  the narrowest part of  the torso, as seen 
from the anterior view. All anthropometric measure-
ments were performed three times and their average 
used for analysis. Participants with no history of  doc-
tor diagnosed diabetes mellitus underwent a 75 g oral 
glucose tolerance test (OGTT) as recommended by the 
WHO29. 
Biochemical analysis
Blood samples were collected from participants after an 
overnight fast. Blood glucose level and glycated haemo-
globin (HbA1c) were measured, respectively, by enzy-
matic hexokinase method and turbidimetric inhibition 
immunoassay (Cobas 6000, Roche Diagnostics, Germa-
ny). Insulin was determined by a microparticle enzyme 
immunoassay (Axsym, Abbot).  High-density lipopro-
tein cholesterol (HDL-C) and triglycerides (TG) were 
estimated by enzymatic colorimetric methods (Cobas 
6000, Roche Diagnostics).  Low-density lipoprotein 
cholesterol (LDL-C) was calculated using Friedwald’s 
formula.
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Definitions and calculations
Body mass index (BMI) was calculated as weight per 
square meter (kg/m2) and waist-hip-ratio (WHR) as 
waist/hip circumferences(cm). Diabetes was based on 
a history of  doctor-diagnosis, fasting blood glucose 
concentration ≥ 7.0 mmol/L (or 126 mg/dL) and/or 
2-hour post-OGTT plasma glucose ≥ 11.1mmol/L (or 
200mg/dL). The homeostatic model assessment of  in-
sulin resistance (HOMA-IR) was calculated according 
to the formula: HOMA-IR= [fasting insulin concentra-
tion (mIU⁄ L) x fasting plasma glucose (mmol⁄ L]/ 22.5; 
while functional β-cells (HOMA-B %) were estimated 
using the formula: 20 × fasting insulin (μIU/ml)/fast-
ing glucose (mmol/ml) − 3.5.  The fasting insulin re-
sistance index (FIRI) was calculated with the formula: 
[fasting insulin (μU/ml) × fasting glucose (mM)]/25 
and the quantitative insulin-sensitivity check index 




Genomic DNA was extracted from peripheral blood 
using the Wizard® Genomic DNA Purification Kit 
(Promega, Madison, WI, USA) according to the man-
ufacturer’s instructions. Briefly, white blood cells were 
lysed, thereafter cellular proteins were removed by salt 
precipitation, and high molecular weight genomic DNA 
left in solution was then concentrated and desalted by 
isopropanol precipitation. A total of  566 participants 
(11.7% males) who consented to genetic analyses were 
genotyped for six single nucleotide polymorphisms 
(SNPs) that have been shown to confer susceptibility to 
T2DM in previous studies elsewhere: ENPP1-rs997509 
and -rs1044498, FTO-9941349 and -rs3751812, TC-
F7L2-rs12255372 and -rs7903146. The SNPs were gen-
otyped using their corresponding Taqman genotyping 
assays (Applied Biosystems, USA) on a BioRad Opti-
ca (Biorad, USA) and validated by sequencing, giving 
100% genotyping concordance for all samples that were 
repeated.
Statistical analysis
General characteristics of  the study group are sum-
marized as count and percentage for dichotomous 
traits, mean and standard deviation (SD) or median 
and 25th-75th percentiles for quantitative traits.  Traits 
were log-transformed to approximate normality, where 
necessary, prior to analysis. SNPs were tested for de-
parture from Hardy-Weindberg Equilibrium (HWE) 
expectation via a chi square goodness of  fit test. Link-
age disequilibrium (LD) was estimated using the D’ 
statistic.  Logistic regression models were used for the 
analysis of  dichotomous traits, assuming both recessive 
and log-additive models for the SNPs.  We investigated 
the association of  each SNP with each trait, overall and 
tested for heterogeneity by major subgroups by adding 
the interaction term of  major grouping variables and 
each SNP to a model that contained the main effects 
of  grouping variable and the relevant SNP. Results cor-
responding to p-values below 5% are described as sig-
nificant. Adjustment for multiple testing was conducted 
via Bonferroni methods. All analyses used the statistical 
software R (version 3.0.0 [2013-04-03], The R Founda-
tion for statistical computing, Vienna, Austria). SNPs 





Of  566 participants that consented for genetic studies, 
480 had complete data for analysis and their clinical 
characteristics are summarized in Table 1.  One hundred 
and fifty eight (32%) individuals had T2DM. As expect-
ed, T2DM-related traits differed significantly according 
to diabetes status. For example, significant differences 
in the distribution of  insulin resistance/sensitivity in-
dicators were observed between the two groups (all p 
< 0.0001, except for glucose/insulin ratio (p = 0.009). 
Participants with diabetes compared to non-diabetics, 
were older (p < 0.0001), had higher body mass index 
(p= 0.023), higher waist circumference and waist-to-hip 
ratio (both p < 0.0001), higher systolic blood pressure 
(130 vs. 121 mmHg, p < 0.0001), and consisted of  a 
higher proportion of  individuals with hypertension 
(77.6% vs. 67.1%, p = 0.018). Furthermore, diabetic in-
dividuals had higher triglycerides (p < 0.0001). 
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Allele distribution and association test
Table 2 shows the allele and genotype distribution of  
SNPs investigated in the present study. None of  the 
SNPs investigated deviated from Hardy Weinberg 
Equilibrium (HWE) in the overall sample (p ≥ 0.103). 











  Overall 
N 328 152     118 129 233     480 
Gender, male  n (%) 18 (5.5) 34 (22.4) <0.000
1 
  16 (13.6) 17 (13.2) 19 (8.1) 0.185   52 (10.8) 










0.793   55.4 
(13.4) 
Mean Systolic blood pressure, 
mmHg (SD) 
121 (18) 130 (22) <0.000
1 
  119 (22) 122 (17) 127 (20) 0.0007   124 (20) 
Mean Diastolic blood pressure, 
mmHg (SD) 
74 (12) 77 (16) 0.076   73 (18) 74 (11) 77 (12) 0.016   75 (14) 
Hypertension, n (%) 220 
(67.1) 
118 (77.6) 0.018   64 (54.2) 93 (72.1) 181 (77.7) <0.000
1 
  338 (70.4) 
Mean Body mass index, kg/m2 
(SD) 
30.1 (7.2) 31.9 (7.2) 0.012   22.0 (2.3) 27.7 (1.4) 36.5 (5.8) <0.000
1 
  30.6 (7.4) 
Mean Waist circumference, cm 
(SD) 
96 (15) 103 (14) <0.000
1 
  81 (10) 93 (6) 109 (11) <0.000
1 
  98 (15) 
Mean Hip circumference, cm 
(SD) 
111 (15) 112 (16) 0.558   96 (9) 106 (6) 122 (13) <0.000
1 
  111 (15) 










  0.88 
(0.08) 
Mean HbA1c, % (SD) 5.7 (0.4) 7.8 (1.9) <0.000
1 
  5.8 (0.9) 6.6 (1.8) 6.4 (1.3) <0.000
1 
  6.3 (1.4) 
Mean Fasting blood glucose, 
mmol/l (SD) 
5.3 (0.7) 9.5 (3.8) <0.000
1 
  5.9 (2.1) 7.0 (3.8) 6.8 (2.8) 0.007   6.6 (3.0) 
Mean  2h glucose, mmol/l (SD) 6.8 (1.7) 13.4 (4.7) <0.000
1 
  7.2 (2.5) 7.7 (3.6) 8.7 (3.9) 0.0008   8.1 (3.5) 
Mean Triglycerides, mmol/l 
(SD) 
1.4 (1.0) 1.8 (0.9) <0.000
1 
  1.2 (1.0) 1.6 (1.1) 1.6 (0.8) 
   
Mean HDL cholesterol, mmol/l 
(SD) 
1.3 (0.3) 1.2 (0.3) 0.0001   1.4 (0.4) 1.3 (0.3) 1.2 (0.3) <0.000
1   1.3 (0.3) 
Mean LDL cholesterol, mmol/l 
(SD) 
3.8 (1.0) 3.8 (1.1) 0.984   3.6 (0.9) 3.8 (1.0) 3.8 (1.0) 0.075   3.8 (1.0) 
Mean Total cholesterol, mmol/l 
(SD) 












1   
7.4 [2.9-
13.2] 



































1   
0.78[0.48-
1.95] 




























































































Abbreviations: CRP,  C-reactive protein; eGFR, estimated glomerularfiltration rate; FIRI, fasting insulin resistance index; HbA1c, glycated 
haemoglobin; HDL ,High Density Lipoproteins; HOMA-B%, functional β-cells; GGT, γ-glutamyltransferase; LDL, Low Density Lipoproteins; 
HOMA-IR, homeostatic model assessment of insulin resistance; QUICKI, the quantitative insulin-sensitivity check index; SD, standard deviation. 
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Within each gene, the SNPs were in linkage disequilib-
rium (LD) in all sub-groups of  the study population 
(D’ ≥ 0.614) (online Figure 1). The SNPs investigated 
showed no differences in the distribution of  alleles and 
genotypes between the study population sub-groups ac-
cording to T2DM and BMI status, except rs7903146. 
The TCF7L2-rs7903146 minor allele was prevalent in 
diabetic compared to non-diabetic individuals (32.2% 
vs. 24.2 %, p = 0.011).
Table 2- Genotype distributions, minor allele frequencies, and unadjusted p-values for comparing genotype distributions 
according to diabetes and BMI status 
 




N 328 152   118 129 233   532 
ENPP1-rs997509          
C/C, n (%) 254 (77.4) 121 (79.6) 0.186  97 (82.2) 
94 (72.9) 184 
(79.0) 
0.342  375 
(78.1) 
C/T, n (%) 70 (21.3) 26 (17.1)   
28 
(15.2) 
33 (25.6) 45 
(19.3) 
  96 
(20.0) 
T/T, n (%) 4 (1.2) 5 (3.3)    3 (2.5) 2 (1.5) 4 (1.7)   9 (1.9) 
T, n (%) 78 (11.9) 36 (11.8) 0.920  34 (14.4) 
37 (14.3) 53 
(11.4) 
0.383  114 
(11.9) 
HWE (p-value) >0.999 0.038   0.095 >0.999 0.511   0.379 
           
ENPP1-rs1044498          
C/C, n (%) 81 (24.7) 41 (27.0) 0.548  33 (28.0) 
35 (25.6) 56 
(24.0) 
0.852  122 
(25.0) 
C/A, n (%) 175 (53.4) 73 (48.0)   
62 
(52.5) 
66 (51.2) 120 
(51.5) 
  248 
(51.7) 
A/A, n (%) 72 (21.9) 38 (25.0)   
23 
(19.5) 
30 (23.3) 57 
(24.5) 
  110 
(22.9) 
A, n (%) 319 (48.6) 149 (49.0)  >0.999  108 (45.8) 
126 (48.8) 234 
(50.2) 
0.538  468 
(48.8) 
HWE (p-value) 0.269 0.629   
0.582 0.861 0.695   0.522 
           
FTO-9941349           
C/C, n (%) 187 (57.0) 73 (48.0) 0.185  63 (53.4) 
64 (49.6) 133 
(57.1) 
0.595  260 
(54.2) 
C/T, n (%) 118 (36.0) 66 (43.4)   
44 
(37.3) 
56 (43.4) 84 
(36.0) 
  184 
(38.3) 
T/T, n (%) 23 (7.0) 13 (8.5)   
11 (9.3) 9 (7.0) 16 
(6.9) 
  36 (7.5) 
T, n (%) 164 (25.0) 92 (30.3) 0.102  66  (28.0) 
74 (28.7) 116 
(24.9) 
0.475  256 
(26.7) 
HWE (p-value) 0.463 0.848   0.492 0.666 0.599   0.642 
           
FTO-rs3751812           
G/G, n (%) 218 (66.5) 93 (61.2) 0.516  75 (63.6) 
79 (61.2) 157 
(67.4) 
0.761  311 
(64.8) 
G/T, n (%) 100 (30.5) 53 (34.9)   38 (32.2) 
46 (35.7) 69 
(29.6) 
  153 
(31.9) 
T/T, n (%) 10 (3.0) 6 (3.9)   5 (4.2) 4 (3.1) 7 (3.0)   16 (3.3) 
T, n (%) 120 (18.3) 65 (21.4) 0.299  48 (20.3) 
54 (20.9) 83 
(17.8) 
0.530  185 
(19.3) 
HWE (p-value) 0.854 0.810   >0.999 0.593 >0.999   0.662 
           
TCF7L2-rs12255372           
G/G, n (%) 221 (67.4) 92 (60.5) 0.305  72 (61.0) 
88 (68.2) 153 
(65.7) 
0.623  313 
(65.2) 
G/T, n (%) 92 (28.0) 50 (32.9)   37 (31.6) 
36 (27.9) 69 
(29.6) 
  142 
(29.6) 
T/T, n (%) 15 (4.6) 10 (6.6)   9 (7.6) 5 (3.9) 11 (4.7) 
  25 (5.2) 
T, n (%) 122 (18.6) 70 (23.0) 0.131  55 (23.3) 
46 (17.8) 91 
(19.5) 
0.295  192 
(20.0) 
HWE (p-value) 0.200 0.364   0.197 0.552 0.403   0.115 
           
TCF7L2-rs7903146           
C/C, n (%) 184 (56.1) 66 (43.4) 0.025  57 (48.3) 
66 (51.2) 127 
(54.5) 
0.330  250 
(52.1) 
C/T, n (%) 129 (39.3) 74 (48.7)   52 (44.0) 
53 (41.1) 98 
(42.1) 
  203 
(42.3) 
T/T, n (%) 15 (4.6) 12 (7.9)   9 (7.6) 10 (7.7) 8 (3.4)   27 (5.6) 
T, n (%) 159 (24.2) 98 (32.2) 0.011  70 (29.7) 
73 (28.3) 114 
(24.5) 
0.275  257 
(26.8) 
HWE (p-value) 0.231 0.196   0.661 >0.999 0.050   0.103 
Abbreviation: ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase gene; FTO, fat mass and obesity-associated gene; 
TCF7L2, transcription factor 7-like 2 gene; HWE, Hardy-Weindberg Equilibrium (HWE p-values are from exact tests) 
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Online Figure 1 – linkage disequilibrium plot (upper panel) and linkage disequilibrium table (lower 
panel) for the six SNP in 480 participants. ENPP1-rs997509 is in linkage disequilibrium (LD) with 
ENPP1-rs1044498 overall (D’=0.968), in participants without diabetes (D’=0.950), in those with 
diabetes (D’=0.999), in normal weight (D’=0.998), overweight (D’=0.999) and obese participants 
(D’=0.939). FTO-9941349 is in linkage disequilibrium (LD) with FTO-rs3751812 overall 
(D’=0.968), in participants without diabetes (D’=0.952) and in those with diabetes (D’>0.999), in 
normal weight (D’=0.937), overweight (D’=0.943) and obese participants (D’=0.999). TCF7L2-
rs12255372 is in linkage disequilibrium (LD) with TCF7L2-rs7903146 overall (D’=0.635), in 
participants without diabetes (D’=0.648) and in those with diabetes (D’=0.602), in normal weight 
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Table 3 –logistic regression models showing the effects of genes on prevalent diabetes 
risk (recessive model). 
 
    Overall   
BMI categories*SNP interaction 
SNP Allele Effects size (95%CI) p   
Recessive model           
ENPP1-rs997509 T/T 4.60 (1.07 to 19.86) 0.040   0.173 
ENPP1-rs1044498 A/A 1.48 (0.89 to 2.47) 0.134   0.059 
FTO-9941349 T/T 1.10 (0.49 to 2.43) 0.822   0.155 
FTO-rs3751812 T/T 0.85 (0.26 to 2.81) 0.937   0.374 
TCF7L2-rs12255372 T/T 1.56 (0.61 to 4.00) 0.361   0.160 
TCF7L2-rs7903146 T/T 1.57 (0.64 to 3.86) 0.329   0.972 
            
Log additive model           
ENPP1-rs997509 T 0.98 (0.62 to 1.54) 0.915     
ENPP1-rs1044498 A 0.99 (0.72 to 1.36) 0.954     
FTO-9941349 T 1.40 (1.00 to 1.96) 0.052     
FTO-rs3751812 T 1.22 (0.83 to 1.80) 0.307     
TCF7L2-rs12255372 T 1.28 (0.89 to 1.83) 0.191     
TCF7L2-rs7903146 T 1.43 (1.00 to 2.04) 0.053     
Models are adjusted for age, sex, BMI and HOMA IR. Effect estimates are odd ratio and 95% confidence 
intervals. Abbreviation: ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase gene; FTO, fat mass and 
obesity-associated gene; TCF7L2, transcription factor 7-like 2 gene. 
with no evidence of  significant statistical interaction 
with BMI categories. The TCF7L2-rs7903146 minor 
allele showed a borderline significant association with 
a high risk of  T2DM [1.43 (1.00 to 2.04); p= 0.053] in 
log-additive models (Table 3). 
In linear analyses adjusted for age, sex, BMI and HOMA 
IR (Table 3), minor allele (T) of  ENPP1-rs997509 was 
associated with a higher risk of  prevalent type 2 dia-
betes under a recessive model [odds ratio (95% con-
fidence interval), 4.60 (1.07 to 19.86); p = 0.040], but 
Although the distribution of  alleles and genotypes of  
the FTO-rs9941349 were not significant between the 
subgroups (Table 2), the minor allele was marginally 
significantly associated with a high risk of  T2DM [1.40 
(1.00 to 1.96); p = 0.052] in log-additive models (Table 
3). The inferred haplotype association analysis showed 
a negative effect of  the rs997509-rs1044498 (TA) and 
rs9941349- rs3751812 (CT) on the risk of  T2DM, how-
ever, the haplotypes occurred at very low frequencies 
(Table 4).
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Discussion
In the present study we demonstrated that, in a reces-
sive model, the minor allele of  the ENPP1 rs997509 is 
associated with a high risk of  T2DM. The presence of  
both ENPP1-rs997509 T alleles conferred a 7% higher 
risk of  prevalent T2DM. However, when analysed as 
a haplotype with rs1044498 (TA), the direction of  as-
sociation changed and this effect was abolished by the 
presence of  the rs1044498 C allele. The haplotype asso-
ciation should be analysed with caution due to the low 
frequency of  the TA haplotype (0.2%). The rs1044498 
minor allele failed to show any association with T2DM 
risk, similar to studies conducted elsewhere in other 
ethnic population groups13,16. This is in contrast to find-
ings of  other studies conducted in Europeans and Chi-
nese12,14 which demonstrated increased risk of  T2DM 
among carriers of  the 121QQ genotype. 
The ENPP1-encoded protein inhibits insulin-signalling 
through interaction with and autophosphorylation of  
the insulin receptor beta-subunit, thus causing insulin 
resistance15. However, in the present study we did not 
find any significant association between ENPP1 SNPs 
and indicators of  insulin resistance/sensitivity. Instead, 
in a previous study we demonstrated that the PPARG-
Pro12 allele was associated with insulin resistance in 
this mixed ancestry cohort21. Like ENPP1, PPARG 
plays a role in insulin sensitivity.  Although the role of  
ENPP1 SNPs in insulin resistance was not evident in 
the present study, combined the findings of  our two 
studies and based on the functions of  the two proteins 
suggest that insulin resistance rather than a defect in 
insulin secretion is a primary defect that may lead to 
the development of  T2DM in this population group. 
Further supporting this hypothesis is the marginal asso-
ciation between TCF7L2 and T2DM without any effect 
on the measure of  beta-cell function (HOMA-B%).  
The two TCF7L2 polymorphisms have been reported 
to influence the development of  T2DM across sever-
Table 4 – Logistic regression models showing the haplotype effects of genes on  
prevalent diabetes risk 
 
        Overall 







Effects size (95%CI) p 
ENPP1-rs997509 ENPP1-rs1044498 CA 48.4 1 (reference)   
    CC 39.6 0.98 (0.70 to 1.38) 0.904 
    TA 0.2 7.213




    TC 11.8 1.01 (0.62 to 1.65) 0.969 
  Global effects       0.753 
            
FTO-rs9941349 FTO-rs3751812 CG 73.1 1 (reference)   
    CT 0.5 4.407(-9) [4.407(-9)  to 4.407(-9)] <0.0001 
    TG 7.6 1.52 (0.88 to 2.64) 0.135 
    TT 18.8 1.34 (0.90 to 2.00) 0.150 





GC 67.8 1 (reference)   
    GT 12.2 1.49 (0.91 to 2.45) 0.110 
    TC 5.3 1.31 (0.64 to 2.73) 0.455 
    TT 14.5 1.41 (0.90 to 2.20) 0.129 
Models are adjusted for age, sex, body mass index and HOMA-IR. Effect estimates are odd ratio and 95% 
confidence intervals for qualitative traits. Abbreviation: ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase 
gene; FTO, fat mass and obesity-associated gene; TCF7L2, transcription factor 7-like 2 gene. 
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al population groups worldwide30-32. While this is the 
case in other population groups, some studies reported 
a weak33,34 or no association35-38. Other studies highlight-
ed the effect of  the TCF7L2 polymorphisms on the 
progression of  T2DM35,39, in some ethnic population 
groups these variants were associated with responses 
to medication40,41, and in others their effect on the dis-
ease was modulated by the type of  diet42-44.Our results 
[1.43 (1.00 to 2.04), p= 0.053] are comparable to those 
reported for other African ethnic population groups17, 
18,20. It is possible that TCF7L2 polymorphisms have 
different effects in various ethnic population groups 
depending on the diet. 
 
Insulin resistance is often related to obesity, and sev-
eral studies have demonstrated that the association of  
ENPP1 and FTO polymorphisms with T2DM is me-
diated by obesity8,9,45,46. However, our study failed to 
show any association between ENPP1, FTO and obesi-
ty. The FTO-rs9941349 was marginally associated with 
an increased risk of  T2DM independent of  obesity in 
our study population. The finding that the rs9941349 
polymorphism is marginally associated with the risk of  
T2DM raises the possibility that this SNP is in linkage 
disequilibrium with a causal locus that is yet to be iden-
tified in mixed ancestry population. In African-Ameri-
cans, this polymorphism was positively associated with 
BMI47. It is possible that the different effects of  the 
rs9941349 are attributable to different linkage dise-
quilibrium blocks harbouring FTO polymorphisms in 
these two ethnic population groups. A comprehensive 
analysis of  FTO polymorphisms in a large population 
of  South African mixed-ancestry is warranted to clarify 
their effect on T2DM and obesity.
 
Limitations
Our study had limitations. We investigated for the first 
time the role of  ENPP1, FTO and TCF7L2 polymor-
phisms in a South African mixed ancestry ethnic pop-
ulation with a unique genetic architecture. However, 
only two SNPs in each gene were studied, and there-
fore we cannot rule out the possible role of  other var-
iants within these genes. Due to financial constraints, 
ancestry informative markers were not used to account 
for population admixture, and there is a possibility that 
population admixture interfered with the association 
analysis. However, when tested none of  the SNPs de-
viated from HWE. Association of  ENPP1, FTO and 
TCF7L2 polymorphisms with high risk of  T2DM may 
have also been confounded by lifestyle effects as re-
ported elsewhere. For example, Moore and co-work-
ers48 showed that the significant association between 
ENPP1 and increased incidence of  T2DM was mediat-
ed by lifestyle or metformin intervention. Ortega-Azor-
in and co-workers49 also found an interaction between 
FTO and mediterranean diet in determining T2DM, 
with carriers of  the FTO-rs9939609 minor allele on a 
low Meddiet having a higher risk of  prevalent T2DM 
than individuals homozygous for the major allele.  In 
a European-American population group, Mattei and 
co-workers50 observed a significant interaction between 
the TCF7L2-rs12255372-TT risk genotype and fat in-
take for changes in BMI, total fat mass, and trunk fat 
mass at 6 month of  lifestyle intervention. The study 
suggested that this effect may help in inducing better 
glycemic control for such individuals predisposed to 
T2DM. It is therefore possible that the marginal associ-
ation between FTO and TCF7L2 polymorphisms may 
be strengthened by inclusion of  environmental factors 
in the analysis, which was not possible in our study 
due to lack of  information on these variables. Due to 
a small sample size, we did not match cases of  T2DM 
and controls by BMI to investigate whether or not obe-
sity modulates the effect of  polymorphisms on T2DM. 
 
Conclusion 
Our study has conducted a genetic association of  
the FTO, ENPP1, and TCF7L2 polymorphisms with 
T2DM and related traits. We found significant associ-
ation between the rs997509 SNP while the rs7903146 
and rs9941349 demonstrated borderline correlation 
with T2DM in the South African mixed ancestry eth-
nic population. A genome-wide association analysis 
in a large sample size is required to identify polymor-
phisms that may predispose mixed ancestry individuals 
to T2DM, accounting for ancestry genetic background. 
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